FEATURED NEWS

• HDA Calls for “Universal” Suspicious Orders Database to Enhance Efforts Against Diversion, Misuse

  February 22, 2018

  In a letter to the Drug Enforcement Administration (DEA) Acting Administrator Robert Patterson, Healthcare Distribution Alliance (HDA) President and CEO John M. Gray called for a “universal” database to support enhanced monitoring of suspicious orders of controlled substances, including controlled opioid drugs. While the DEA has indicated that it currently is developing a suspicious orders database for its own use, HDA’s latest letter calls for the agency to share this data, and DEA’s advanced analytical tools, with state regulators and state/local law enforcement officials to improve information sharing and coordination.

• HDA Statement on New DEA Assessment Tool and Data

  February 15, 2018

  Following the Drug Enforcement Administration’s (DEA) announcement yesterday regarding a new assessment tool for controlled substance orders, Healthcare Distribution Alliance (HDA) President and CEO John M. Gray issued the following statement.

• HDA Announces Availability of API Certification Program for Origin

  February 14, 2018

  The Healthcare Distribution Alliance (HDA) and ValueCentric today announced the introduction of a new certification program for third-party solution providers to exchange data with Origin on behalf of their manufacturer and distributor clients using an Application Programming Interface (API). Adents, a leading provider of premier and versatile serialization and track-and-trace solutions, is the first solution provider that has entered to meet the certification.

• Coalition of Public Health Organizations and Supply Chain Partners Launch Educational Initiative to Reduce Opioid Abuse and Misuse

  February 6, 2018

  Today, leading partners across healthcare, public health and the pharmaceutical supply chain joined together to launch Allied Against Opioid Abuse (AAOA), a national education and awareness initiative to help combat the nation’s opioid abuse epidemic.

• TraceLink Will Dismiss Litigation Claims Against Healthcare Distribution Alliance (HDA)

  February 5, 2018

  TraceLink Inc., and the Healthcare Distribution Alliance (HDA) today announced that TraceLink will dismiss litigation claims that it asserted against HDA, which stated that HDA participated in conspiracies to unreasonably restrain trade and to monopolize. TraceLink agreed to the dismissal as they have resolved the misunderstandings that led to their dispute. TraceLink and HDA will work together with other industry players to propose interoperable standards and guidelines for pharmaceutical product master data, with the purpose of enabling compliance with the Drug Supply Chain Security Act of 2013. The two organizations will collaborate and submit standards proposals to GS1 US Healthcare for consideration. To facilitate the development of such proposed standards, HDA will convene a working group in which TraceLink and other vendors and supply chain stakeholders will be invited to participate. The goal of the work group is to provide a forum to develop a proposal for ultimate submission to GS1 US for its consideration. HDA’s Origin and TraceLink’s Life Sciences Cloud will comply with any standard adopted by GS1 US for master data exchange.